1-6 of 6
Jianguo Zhi
Close
Sort by
Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Karen Yee, MD, Giovanni Martinelli, MD, Norbert Vey, MDPhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Karen Seiter, MD, Sarit Assouline, MD MSc, Mark Drummond, MD PhD, Sung-Soo Yoon, MDPhD, Margaret Kasner, MD, Je-Hwan Lee, MD PhD, Kevin R. Kelly, MD PhD, Steven Blotner, PhD, Brian Higgins, Steven Middleton, PhD, Gwen Nichols, MD, Gong Chen, PhD, Hua Zhong, PhD, William E. Pierceall, PhD, Jianguo Zhi, PhD, Lin-Chi Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 116.
https://doi.org/10.1182/blood.V124.21.116.116
Published: 2014
Journal Articles

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Karen Yee, MD, Giovanni Martinelli, MD, Sarit Assouline, MD, Margaret Kasner, MD, Norbert Vey, MD PhD, Kevin R. Kelly, MD, PhD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Michael Dennis, FRCP, FRCPath, Karen Seiter, MD, Steven Blotner, PhD, Lori Jukofsky, Steven Middleton, PhD, Jianguo Zhi, PhD, Gong Chen, PhD, Hua Zhong, PhD, Gwen Nichols, MD
Journal: Blood
Blood (2013) 122 (21): 498.
https://doi.org/10.1182/blood.V122.21.498.498
Published: 2013
Journal Articles

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Michael Andreeff, MD, PhD, Kevin R. Kelly, MD, Karen Yee, MD, Sarit Assouline, Roger Strair, MD, PhD, Leslie Popplewell, MD, David Bowen, Giovanni Martinelli, MD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Paresh Vyas, MD, Mark Kirschbaum, MD, Swaminathan Padmanabhan Iyer, MD, Kensuke Kojima, MD, PhD, David Geho, MD, Steven Blotner, PhD, Suzanne Cheng, PhD, Lyubomir Vassilev, PhD, Meichun Ding, PhD, Jianguo Zhi, PhD, Steven Middleton, PhD, Gwen Nichols, MD
Journal: Blood
Blood (2012) 120 (21): 675.
https://doi.org/10.1182/blood.V120.21.675.675
Published: 2012
Journal Articles

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Vivian Ruvolo, Anas Younes, MD, Wei Wei, Marina Konopleva, MD, PhD, Seshagiri Duvvuri, Xuelin Huang, PhD, Lin Wu, PhD, Lori Jukofsky, Lyubomir Vassilev, PhD, Jianguo Zhi, PhD, David Geho, MD, Gwen Nichols, MD
Journal: Blood
Blood (2011) 118 (21): 1545.
https://doi.org/10.1182/blood.V118.21.1545.1545
Published: 2011
Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

David Dornan, Olivia Spleiss, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, Annika Dufour, Jianguo Zhi, Tadeusz Robak, Sergey I. Moiseev, Anna Dmoszynska, Philippe Solal-Celigny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Boris V. Afanasiev, Loree Larratt, Viktor A. Rossiev, Isabelle Bence-Bruckler, Christian H. Geisler, Marco Montillo, Michael K. Wenger, Martin Weisser
Journal: Blood
Blood (2010) 116 (20): 4212–4222.
https://doi.org/10.1182/blood-2010-03-272765
Published: 2010
Journal Articles

Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling.

Jing Li, Ph.D., Jianguo Zhi, Ph.D., Michael K. Wenger, MD, Nancy Valente, MD, Jennifer Visich, Ph.D.
Journal: Blood
Blood (2009) 114 (22): 1742.
https://doi.org/10.1182/blood.V114.22.1742.1742
Published: 2009